ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 249 entries already.
With the promise of transformative treatments, cell therapies are rising across oncology, regenerative medicine, and stem cell applications. PL BioScience supports this evolution with Human Platelet Lysate (HPL) and soon, the first artificial HPL, while expanding production in Aachen to continue to deliver this high-quality cell culture supplement worldwide.
Pharmahungary Group (PH) developed miRNAtarget, a miRNA discovery software tool based on miRNA-mRNA molecular networks. PH holds patent families on 4 cardio-protective microRNAs families (protectomiRs) and seeks for co-development partners and/or early stage investors. PH also offers its miRNA discovery and development service platform that includes efficacy testing from in vitro to large animal models in various therapeutic areas.
Capital is tight and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures.
Antibody-drug conjugates (ADCs) hinge on the antibody, not merely the payload or linker. Antibody precision defines efficacy, safety and therapeutic window. Emerging antibody formats – bispecifics, conditional designs and TCR-mimics – expand target space, demanding rigorous engineering to realise next-generation ADC potential.
Earlier guidelines such as ICH Q2(R1) and USP <1224>, <1225>, and <1226> viewed analytical method validation as a discrete activity focused primarily on chromatographic procedures. With ICH Q14, ICH Q2(R2), and USP <1220>, a life-cycle approach now considers variability and improves reliability, supported by tools like DoE, multivariate statistics, and digital technologies enabling Quality by Design and risk-based systems.
Efficiency and flexibility are key factors to stay competitive in the bioprocess field. With this aim in mind, the SciVario twin is a controller for small and bench-scale bioreactors, designed to save time and costs during process development and optimization.
In Life Sciences, SAP transformations for midsize CDMOs are nothing short of complex. But integrating a newly acquired site into an existing SAP landscape is a different matter entirely. At Tenthpin, we took a bold step by designing a new SAP S/4HANA template from the ground up to a new site for a leading CDMO; and then successfully deploying it to another newly acquired site in less than 10 months.
In this interview Dr. Martin Stieler, founder and CEO of BIMOVIS, introduces his company and the importance of structural biology in biotech and pharmaceutical industries, and highlights how BIMOVIS helps unlock the full potential of biomolecular insights to advance drug development and strengthen R&D pipelines.
Fifty years after the invention of hybridoma technology, biologics have become a cornerstone of oncology drug discovery and development. From the first monoclonal antibody approval in 1995 to today’s complex antibody formats and cell-based therapies, biologics are reshaping cancer drug discovery. Yet, despite remarkable progress, the urgent need for novel targets that can exploit recent technological developments remains high.
T3 Pharmaceuticals shows how a biotech can move from first experiments to a major international deal keeping pace – and roots – in the Basel Area. The team built, tested and scaled inside Switzerland Innovation Park Basel Area’s Main Campus. Flexible private labs, certified shared facilities and an on-site expert community cut friction at every step. The result: faster iteration, smarter use of capital and a clear path from seed to global relevance — all inside Europe’s densest life sciences cluster.